What is the 13F Pro Quality Score for RCEL?

13F Pro ranks AVITA Medical, Inc. (RCEL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RCEL's current score at https://13fpro.ai/research/RCEL (free sign-up required for the full ranking).

Which hedge funds own the most RCEL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RCEL include ORBIMED ADVISORS, ORBIMED ADVISORS, EverSource Wealth Advisors,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RCEL as soon as new 13F filings post.

Where does 13F Pro source RCEL data?

All AVITA Medical, Inc. fundamentals and ownership data come directly from SEC EDGAR. AVITA Medical, Inc. files with the SEC under CIK 1762303. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RCEL in?

AVITA Medical, Inc. (RCEL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RCEL research updated on 13F Pro?

RCEL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AVITA Medical, Inc.(RCEL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1762303 RCEL stock profile & AI dashboard →

13F Pro Quality Score

29.6/100

Rank #2,394 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

84.1/100

Profitability

9.7/100

Balance Sheet

1.1/100

Earnings Quality

30.0/100

Free Cash Flow

9.3/100

Institutional Flow

100.0/100

Revenue Scale

14.2/100

Dilution Risk

13.8/100

RCEL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AVITA Medical, Inc. (RCEL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RCEL at 29.6/100 on a 32-signal composite quality model, placing it at rank #2,394 of 2,879 stocks — the bottom half of the AI-ranked universe. RCEL scores in the top quartile across institutional flow (100.0), revenue growth (84.1). Areas of concern include balance sheet strength (1.1) and free cash flow (9.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), AVITA Medical, Inc. reports quarterly revenue of $19.3M, net income of $-10.6M, an operating margin of -45.7%. Top institutional holders of RCEL by reported 13-F value include ORBIMED ADVISORS, ORBIMED ADVISORS, EverSource Wealth Advisors,, based on the most recent SEC filings. RCEL trades on the Nasdaq exchange and files with the SEC under CIK 1762303. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RCEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AVITA Medical, Inc. directly from SEC EDGAR. AVITA Medical, Inc.'s 13F Pro composite quality score has ranged between 20 and 30 since 2021, currently 29.6 — a stable long-term trajectory across 18 quarterly and live scoring snapshots.

Revenue

Q3 2026

$19.3M

Net Income

Q3 2026

$-10.6M

Free Cash Flow

Q3 2026

$-10.1M

Operating Margin

Q3 2026

-45.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+3.1% YoY

$929.0KFY 2018

FY17 $901.4KFY18 $929.0K

Net Income

$-12.7MFY 2018

FY17 —FY18 $-12.7M

Operating Income

$-13.8MFY 2018

FY17 —FY18 $-13.8M

EPS (Diluted)

$0.01FY 2018

FY17 —FY18 $0.01

Total Assets

+216.1% YoY

$23.0MFY 2018

FY17 $7.3MFY18 $23.0M

Op. Cash Flow

$-13.0MFY 2018

FY17 —FY18 $-13.0M

Metric	FY 2018	FY 2017
Revenue	$929.0K +3.1%	$901.4K
Net Income	$-12.7M	—
Operating Income	$-13.8M	—
EPS (Diluted)	$0.01	—
Total Assets	$23.0M +216.1%	$7.3M
Operating Cash Flow	$-13.0M	—

AI Insight: RCEL Financial Trends

RCEL remains unprofitable with stagnant $17–20M quarterly revenue; cash burn persists despite modest operating margin improvement.

• Operating margin improved to –47% in Q1 2026 from –80% in Q2 2024, though company remains deeply unprofitable.

• Operating cash burn moderating: Q1 2026 outflow of $10M compares favorably to $13M in Q2 2024.

• Revenue flat to declining: $19M in Q1 2026 vs. $15M in Q2 2024, with no sustained growth trajectory evident.

⚠ Equity deteriorated to –$23M in Q1 2026 from +$24M in Q2 2024; negative equity signals balance-sheet stress.

⚠ Total debt stable around $41–46M while equity erodes; leverage ratio deteriorating sharply.

AI Insight: RCEL Ratio Trends

Operating margin inflection underway: Q1 2026 shows -45.7%, best in 9 quarters, but profitability remains deeply negative across all metrics.

• Operating margin improved from -102.8% in Q2 2024 to -45.7% in Q1 2026, a 57-point swing toward breakeven.

• Net profit margin stabilized at -55.1% in Q1 2026, up 28 points from -82.9% low in Q3 2024.

• ROA remains severely depressed at -82.3% in Q1 2026; company burning cash on minimal asset base.

⚠ Debt/equity spiked to 9.39x in Q4 2024, then data gaps suggest restructuring or deleveraging actions—status unclear.

⚠ Despite 57pp OpMargin gain, company remains unprofitable; path to positive ROIC and cash generation unproven.

Get alerted when RCEL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AVITA Medical, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RCEL

ORBIMED ADVISORS LLC
$154.4M40,966,100 sh
ORBIMED ADVISORS LLC
$42.5M41,044,895 sh
EverSource Wealth Advisors, LLC
$9.7M102,251 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.9M1,335,152 sh
BlackRock, Inc.
$4.2M1,133,126 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.0M542,974 sh
STATE STREET CORP
$1.6M429,022 sh
VANGUARD FIDUCIARY TRUST CO
$715.7K193,436 sh
NORTHERN TRUST CORP
$677.8K183,181 sh
MORGAN STANLEY
$583.2K157,621 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$154.4M	40,966,100
ORBIMED ADVISORS LLC	$42.5M	41,044,895
EverSource Wealth Advisors, LLC	$9.7M	102,251
VANGUARD CAPITAL MANAGEMENT LLC	$4.9M	1,335,152
BlackRock, Inc.	$4.2M	1,133,126
GEODE CAPITAL MANAGEMENT, LLC	$2.0M	542,974
STATE STREET CORP	$1.6M	429,022
VANGUARD FIDUCIARY TRUST CO	$715.7K	193,436
NORTHERN TRUST CORP	$677.8K	183,181
MORGAN STANLEY	$583.2K	157,621

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RCEL on your watchlist

Track score changes the day AVITA Medical, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RCEL a good stock to buy?

13F Pro's AI-powered analysis of AVITA Medical, Inc. (RCEL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RCEL are available on the RCEL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RCEL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RCEL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AVITA Medical, Inc.'s investment landscape.